LITT and Pembrolizumab in Recurrent Brain Metastasis
Conditions: Melanoma; Non-small Cell Lung Carcinoma (NSCLC); Renal Cell Carcinoma (RCC); Brain Metastases Intervention: Combination Product: LITT + Pembrolizumab Sponsors: University of Florida; Monteris Medical Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | Carcinoma | Melanoma | Neurology | Non-Small Cell Lung Cancer | Research | Skin Cancer